- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Gene Fusion Testing Market Sees Opportunities in Personalized Medicine and Early Cancer Detection
Report projects 12% CAGR growth through 2030 driven by rising cancer rates, adoption of advanced sequencing, and emerging markets
Published on Feb. 6, 2026
Got story updates? Submit your updates here. ›
A new report from Research and Markets projects the global gene fusion testing market will grow at a 12% CAGR from 2025 to 2030, reaching $993.6 million. Key drivers include the rising adoption of personalized medicine, increasing awareness and early cancer detection programs, and emerging markets. The report analyzes market trends, technology advancements, and the competitive landscape, including profiles of leading companies in the space.
Why it matters
Gene fusion testing plays a critical role in cancer research and treatment by identifying specific genetic abnormalities that can guide personalized therapies. As cancer rates rise globally, the demand for advanced diagnostic tools like gene fusion testing is growing, especially in developing markets where access to early detection programs is expanding.
The details
The report examines the gene fusion testing market across technology (NGS, PCR, FISH, IHC), disease indication (solid tumors, hematological cancers), and end-user (pharma/biotech, hospitals, academic research). It highlights emerging technologies like single-molecule long-read sequencing, CRISPR-based fusion detection, and AI-powered analysis. The competitive landscape features leading players such as Illumina, Thermo Fisher, Guardant Health, and QIAGEN.
- The report uses 2024 as the base year, with estimates for 2025 and projections through 2030.
- The report was published on February 6, 2026.
The players
ResearchAndMarkets.com
The world's leading source for international market research reports and data.
Illumina Inc.
A leading developer of next-generation sequencing technologies.
Thermo Fisher Scientific Inc.
A multinational biotechnology company that provides analytical instruments, reagents, and software.
Guardant Health Inc.
A precision oncology company focused on developing blood tests for cancer screening and treatment guidance.
QIAGEN
A global provider of sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research.
The takeaway
As cancer diagnoses rise globally, the gene fusion testing market is poised for significant growth driven by the increasing adoption of personalized medicine, expansion of early detection programs, and emerging opportunities in developing markets. Leading diagnostic companies are investing in advanced sequencing and AI technologies to meet this growing demand for more precise, targeted cancer testing and treatment.
